Pipeline progress and portfolio management of the top 30 pharma companies over the past two decades.

ABSTRACT: For pharmaceutical companies, it is essential to define their long-term corporate strategy. This especially involves the pipeline progress of pharmaceuticals and portfolio management. The objective of this study was to give a broad overview of study durations of the clinical trials from the top 30 pharmaceutical companies worldwide and to investigate what could possibly impact these study durations (e.g., indication areas, companies themselves, etc.) We worked with the clinicaltrials.gov database to examine the pipeline (phase 1-3) and portfolio (after regulatory approval) of the top 30 pharma companies worldwide over 20 years (from 2000-2020). We further calculated the study duration of each clinical study as the difference between the start date and end date. To analyze changes in our me

SUBMITTER: Bussgen M 

PROVIDER: S-EPMC10540351 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature